Mitoketoscins: mitochondrial-based therapeutics targeting ketone metabolism in cancer cells

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 11667639
APP PUB NO 20200148688A1
SERIAL NO

16626426

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

The present disclosure relates to compounds that bind to at least one of ACAT1/2 and OXCT1/2 and inhibit mitochondrial ATP production, referred to herein as mitoketoscins. Methods of screening compounds for mitochondrial inhibition and anti-cancer properties are disclosed. Also described are methods of using mitoketoscins to prevent or treat cancer, bacterial infections, and pathogenic yeast, as well as methods of using mitoketoscins to provide anti-aging benefits. Specific mitoketoscin compounds are also disclosed.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddress
LUNELLA BIOTECH INCOTTAWA ON K1Z 1A1

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Lisanti, Michael P Fulton, US 51 52
Sotgia, Federica Fulton, US 47 46

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
3.5 Year Payment $1600.00 $800.00 $400.00 Dec 6, 2026
7.5 Year Payment $3600.00 $1800.00 $900.00 Dec 6, 2030
11.5 Year Payment $7400.00 $3700.00 $1850.00 Dec 6, 2034
Fee Large entity fee small entity fee micro entity fee
Surcharge - 3.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 7.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00